{"id":"W2982296199","doi":"10.1016/s0140-6736(19)32597-8","title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":1367,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Seattle Children's Research Institute; National Heart, Lung, and Blood Institute; Vertex Pharmaceuticals; National Institutes of Health; Cystic Fibrosis Foundation Therapeutics","keywords":"Ivacaftor; Cystic fibrosis; Regimen; Medicine; Double blind; Internal medicine; Mutation; Clinical trial; Genetics; Alternative medicine; Pathology; Biology; Cystic fibrosis transmembrane conductance regulator; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}